

07th August, 2023

The Dy. General Manager (Listing Dept.) BSE Limited,
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

The Manager – Listing Dept., National Stock Exchange of India Ltd., Exchange Plaza, 5th Floor, Plot No. C/1, G. Block, Bandra - Kurla Complex, Bandra (E), Mumbai – 400 051 (NSE Scrip Code: TORNTPHARM)

Dear Sir,

Re: Proceedings of 50th Annual General Meeting of the Company held on 07th August, 2023

In terms of Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we hereby inform you that the following business was transacted at the 50th Annual General Meeting (AGM) of the Company held through Video Conferencing on 07th August, 2023.

- Approval and adoption of Standalone and Consolidated Financial Statements as at 31st March, 2023, including the Audited Balance Sheet as at 31st March, 2023, the Statement of Profit and Loss for the year ended on that date and reports of the Board of Directors and Auditors thereon.
- 2. Confirmation of payment of interim dividend of ₹ 14.00 per equity share of fully paid up face value of ₹ 5.00 each and declaration of final dividend of ₹ 8.00 per equity share of fully paid up face value of ₹ 5.00 each for the financial year ended 31st March, 2023.
- 3. Appointment of a Director in place of Samir Mehta (holding DIN 00061903), Director, who retires by rotation and being eligible, offers himself for re-appointment.
- 4. Ratification of remuneration of cost auditors of the Company for the year 2023-24.
- 5. Issuance of Equity Shares including Convertible Bonds / Debentures.
- 6. Alteration of Articles of Association of the Company
- 7. Appointment of Nikhil Khattau (holding DIN 00017880) as an Independent Director of the Company

The above business were transacted by Remote e-voting and e-voting at the meeting as required under Companies Act, 2013, Listing Regulations and Ministry of Corporate Affairs General circular no. 20 read with Circular nos. 14 & 17 of 2020 and 10 of 2022. Declaration of Results of



Voting along with Scrutinizer's Report and Results of voting as required under Regulation 4-	4(3)
of Listing Regulations will be disclosed to the Stock Exchanges separately.	

Kindy take note of the above.

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED

CHINTAN M. TRIVEDI COMPANY SECRETARY